Want to be in the loop?
subscribe to
our notification
Business News
VIỆT NAM'S PHARMACEUTICAL MARKET SEES MAJOR M&A DEAL
This deal, valued at over VNĐ5.73 trillion (about US$220.6 million), underscores the increasing attractiveness of Việt Nam's pharmaceutical industry to foreign investors.
The headquarters of Imexpharm in Đồng Tháp Province. — Photo courtesy of the company
HÀ NỘI — The Vietnamese pharmaceutical sector has recently witnessed one of its largest mergers and acquisitions (M&A) to date, with Livzon Pharmaceutical Group Inc. of China acquiring approximately 64.81 per cent of Imexpharm Pharmaceutical Joint Stock Company (IMP).
The deal, valued at over VNĐ5.73 trillion (about US$220.6 million), underscores the increasing attractiveness of Việt Nam's pharmaceutical industry to foreign investors.
Livzon, through its Singapore-based subsidiary Lian SGP Holding Pte. Ltd., will purchase shares from existing stakeholders, including SK Investment Vina III Pte. Ltd., which holds a 47.69 per cent stake, alongside smaller investors.
Once the transaction is finalised, expected within nine months, Imexpharm will become an indirect subsidiary of Livzon, with its financial results integrated into Livzon's consolidated reports.
This acquisition marks a significant divestment by SK Group, a major South Korean conglomerate, reflecting a strategic restructuring of its investment portfolio in Việt Nam.
Meanwhile, Livzon's decision to enter the Vietnamese market highlights its ambition to diversify revenue streams and mitigate risks associated with domestic market fluctuations.
Established in 1985 and headquartered in Zhuhai, China, Livzon is a prominent player in the pharmaceutical industry, specialising in research, development and manufacturing of various pharmaceutical products, including biopharmaceuticals and traditional Chinese medicines.
With over 9,000 employees and listings on both the Hong Kong and Shenzhen stock exchanges, Livzon possesses strong financial resources and extensive market expertise.
In recent years, Livzon has actively pursued international expansion, with foreign revenue accounting for nearly 15 per cent of total sales in 2024. The acquisition of Imexpharm represents a strategic move to penetrate one of Southeast Asia's fastest-growing pharmaceutical markets.
Imexpharm, founded in 1977 and recognised as one of Việt Nam's leading pharmaceutical companies, has established a solid reputation, particularly in the antibiotic sector, where it commands approximately 10 per cent of the domestic market share.
The company has made significant investments in high-standard manufacturing facilities compliant with European standards (EU-GMP), which positions it well for both domestic sales and export opportunities.
In 2024, Imexpharm reported revenues of over VNĐ2.2 trillion, an 11 per cent increase from the previous year, and a net profit of VNĐ320 billion.
The company aims for an average annual revenue growth of 15 per cent through 2030, with plans to further expand its manufacturing capabilities, particularly in cardiovascular, diabetes and gastrointestinal treatments. — BIZHUB/VNS
Source: VNS
Related News
MEMBER CORNER / PROMOTIONS
VIETNAM'S MANUFACTURING STORY HAS CHANGED IN 2026
Vietnam is no longer attracting investment solely because of its competitive costs. Today, global manufacturers are increasingly choosing Vietnam for its expanding industrial ecosystem, resilient supply chains and growing role in high-value sectors such as semiconductors, electronics and advanced manufacturing.
BANKING / FINANCE / INSURANCE / TAX
VIETNAM NEEDS OVER $200BN FROM STOCK MARKET IN NEXT 5 YEARS
Speaking at the event, Bui Hoang Hai, vice-chairman of the State Securities Commission of Vietnam, said total investment demand in the 2026-30 period is estimated at VND38,000 trillion ($1.4 trillion). The state budget can only provide approximately VND8,500 trillion ($323 billion), or 20 percent, leaving the remaining 80 percent to be sourced from private and international capital.
VIETNAM ECONOMY INVESTMENT
HUNG YEN BUILDS DIGITAL FOUNDATIONS TO DRIVE LONG-TERM GROWTH
From strengthening data infrastructure to developing AI platforms, Hung Yen province is enhancing governance capacity while laying the groundwork for the growth of its digital economy. Hung Yen, about 50-60km southeast of Hanoi, has maintained steady momentum in implementing its digital transformation agenda, creating a stronger foundation for the province to advance science, technology, and innovation.
VIETNAM ECONOMY INVESTMENT
CHINESE INVESTMENT WAVE OPENS NEW DOORS
As Chinese companies move beyond factory relocation to ecosystem-driven investment, Vietnam has a rare opportunity to evolve from a low-cost production base into a strategic node in regional value chains. When global companies first diversified supply chains, the focus was largely on relocating manufacturing capacity.
VIETNAM ECONOMY INVESTMENT
VIỆT NAM STEPS UP EXPORT TO ACHIEVE US$550-BILLION TARGET
Việt Nam is intensifying efforts to sustain export momentum in the second half of 2026 as the country works towards its target of US$550 billion in export revenue for the year, despite continuing uncertainties in global trade. Statistics show that exports reached $266.5 billion in the first six months, meaning the economy needs to generate around $245.5 billion more during the remainder of the year to meet the annual goal.
VIETNAM ECONOMY INVESTMENT
ASIA POWERS VIETNAM’S SHRIMP BOOM, LEAVING THE WEST BEHIND
In the first half of 2026, Vietnam's shrimp exports surpassed the US$2.3 billion mark, driven largely by booming demand from China and a lobster craze. But behind that growth figure lies a lopsided picture: Asia is carrying the load, while the U.S. and Europe have yet to break out. These days, a container of frozen shrimp leaving a Ho Chi Minh City port is more likely to cross the East Vietnam Sea to Shanghai than the Pacific to Los Angeles.
Events Sponsors
